DDInter1955 DDInter1658
Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Zafirlukast {u} (Compound) resembles {v} (Compound) Tolvaptan
Zafirlukast {u} (Compound) treats {v} (Disease) asthma
Zafirlukast {u} (Compound) binds {v} (Gene) CYSLTR2
Zafirlukast {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Zafirlukast {u} (Compound) causes {v} (Side Effect) Hyperbilirubinaemia
Zafirlukast {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Zafirlukast {u} may cause a minor interaction that can limit clinical effects when taken with {v} Citalopram
Zafirlukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Zafirlukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Zafirlukast {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Zafirlukast (Compound) resembles Tolvaptan (Compound)
Zafirlukast (Compound) treats asthma (Disease)
Zafirlukast (Compound) binds CYSLTR2 (Gene)
Zafirlukast (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Zafirlukast (Compound) causes Hyperbilirubinaemia (Side Effect)
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Donepezil
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Citalopram
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib
Zafirlukast may lead to a major life threatening interaction when taken with Lomitapide